Product
Larazotide
Aliases
AT1001, Larazotide Acetate
5 clinical trials
9 indications
Indication
Rheumatoid ArthritisIndication
Long COVIDIndication
Long COVID-19Indication
Post-Acute COVID-19 SyndromeIndication
Post-Acute Sequelae of COVID-19Indication
COVID-19Indication
Axial SpondyloarthritisIndication
Superficial ThrombophlebitisClinical trial
A Single Dose, Double-Blind, Parallel Arm, Comparative Pharmacokinetic Study of DRL_AB, US Licensed Reference Abatacept (Orencia®) and EU Approved Reference (Orencia®), Administered by the Subcutaneous Route to Male Normal Healthy VolunteersStatus: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
Phase 2a Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Larazotide (AT1001) for the Treatment of Long COVID in Children and Young AdultsStatus: Recruiting, Estimated PCD: 2025-03-31
Clinical trial
A Phase 2a (Proof of Concept), Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AT1001 for the Treatment of COVID-19 Related Multisystem Inflammatory Syndrome in Children (MIS-C)Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Individualizing Anti-Inflammatory Medications for Adults With Axial Spondyloarthritis: A Series of N-of 1 TrialsStatus: Completed, Estimated PCD: 2023-08-11
Clinical trial
INvestigating SIGnificant Health TrendS in the Management of Superficial Vein Thrombosis (INSIGHTS-SVT)Status: Completed, Estimated PCD: 2019-08-30